Skip to main content

Table 2 Comparison between group of patients with normal overall Montreal score and those patients with abnormal score

From: Chemotherapy-induced cognitive impairment in hematological malignancies

 

Overall Montreal score

Chi-square

Normal

Cognitive impairment

N

%

N

%

χ 2

p value

Sex

Male

40

70.18

57

61.29

1.22

0.26

Female

17

29.82

36

38.71

Diagnosis

AML

17

29.82

28

30.11

14.91

0.02

ALL

8

14.04

7

7.53

CML

11

19.30

5

5.38

CLL

6

10.53

14

15.05

MDS

0

0.00

2

2.15

Lymphoma

4

7.02

21

22.58

Myeloma

11

19.30

16

17.20

Chemotherapy

Intensified protocol

23

40.35

33

35.48

5.76

0.12

TKIs

8

14.04

5

5.38

Velcade

11

19.30

16

17.20

Others

15

26.32

39

41.94

Route of chemotherapy

Oral

10

17.54

5

5.38

5.81

0.01

Parenteral

47

82.46

88

94.62

Comorbidities

No

53

92.98

51

54.84

26.52

< 0.001

HTN

0

0.00

16

17.20

DM

2

3.51

8

8.60

Viral hepatic infection

2

3.51

6

6.45

More than one

0

0.00

12

12.90

Remission status

Remitted

42

73.68

61

65.59

1.07

0.30

Resistant or refractory

15

26.32

32

34.41